Qure.ai, a NYC-based company delivering AI-augmented detection for Tuberculosis (TB), Lung Cancer and Stroke, received an investment from Merck Global Health Innovation Fund.
The amount of the deal, which was part of its Series D round, was not disclosed.
The company intends to use the funds to invest into foundation models for artificial intelligence (AI) in imaging and expand geographical reach of its AI-powered imaging solutions into the US market.
Led by CEO Prashant Warier, Qure.ai has delivered AI-augmented detection for Tuberculosis (TB), Lung Cancer and Stroke at over 2700 imaging sites, across more than 90 countries. It has clearance from the United States Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) for its AI-powered Chest X-ray lung nodule detection solution (qXR-LN), device designation for TB solution (qSpot-TB), an AI-enabled head CT tool to expedite the detection, triage and quantification of traumatic brain injuries and stroke (qER-Suite), plus multiple other plain film X-ray emergency room findings.
Merck had previously invested in Qure.ai, as part of its impact investing portfolio led by the Merck Office of Social Business Innovation.
FinSMEs
26/06/2024